Cargando…

Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions

Robust experiment evidence suggests that prolactin can enhance beta-cell proliferation and increase insulin secretion and sensitivity. Apart from acting as an endocrine hormone, it also function as an adipokine and act on adipocytes to modulate adipogenesis, lipid metabolism and inflammation. Severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Hung-Yu, Chen, Su-Mei, Li, Wan-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012161/
https://www.ncbi.nlm.nih.gov/pubmed/36993818
http://dx.doi.org/10.3389/fcdhc.2023.935872
_version_ 1784906562552201216
author Chien, Hung-Yu
Chen, Su-Mei
Li, Wan-Chun
author_facet Chien, Hung-Yu
Chen, Su-Mei
Li, Wan-Chun
author_sort Chien, Hung-Yu
collection PubMed
description Robust experiment evidence suggests that prolactin can enhance beta-cell proliferation and increase insulin secretion and sensitivity. Apart from acting as an endocrine hormone, it also function as an adipokine and act on adipocytes to modulate adipogenesis, lipid metabolism and inflammation. Several cross-sectional epidemiologic studies consistently showed that circulating prolactin levels positive correlated with increased insulin sensitivity, lower glucose and lipid levels, and lower prevalence of T2D and metabolic syndrome. Bromocriptine, a dopamine receptor agonist used to treat prolactinoma, is approved by Food and Drug Administration for treatment in type 2 diabetes mellitus since 2009. Prolactin lowering suppress insulin secretion and decrease insulin sensitivity, therefore dopamine receptor agonists which act at the pituitary to lower serum prolactin levels are expected to impair glucose tolerance. Making it more complicating, studies exploring the glucose-lowering mechanism of bromocriptine and cabergoline have resulted in contradictory results; while some demonstrated actions independently on prolactin status, others showed glucose lowering partly explained by prolactin level. Previous studies showed that a moderate increase in central intraventricular prolactin levels stimulates hypothalamic dopamine with a decreased serum prolactin level and improved glucose metabolism. Additionally, sharp wave-ripples from the hippocampus modulates peripheral glucose level within 10 minutes, providing evidence for a mechanistic link between hypothalamus and blood glucose control. Central insulin in the mesolimbic system have been shown to suppress dopamine levels thus comprising a feedback control loop. Central dopamine and prolactin levels plays a key role in the glucose homeostasis control, and their dysregulation could lead to the pathognomonic central insulin resistance depicted in the “ominous octet”. This review aims to provide an in-depth discussion on the glucose-lowering mechanism of dopamine receptor agonists and on the diverse prolactin and dopamine actions on metabolism targets.
format Online
Article
Text
id pubmed-10012161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100121612023-03-28 Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions Chien, Hung-Yu Chen, Su-Mei Li, Wan-Chun Front Clin Diabetes Healthc Clinical Diabetes and Healthcare Robust experiment evidence suggests that prolactin can enhance beta-cell proliferation and increase insulin secretion and sensitivity. Apart from acting as an endocrine hormone, it also function as an adipokine and act on adipocytes to modulate adipogenesis, lipid metabolism and inflammation. Several cross-sectional epidemiologic studies consistently showed that circulating prolactin levels positive correlated with increased insulin sensitivity, lower glucose and lipid levels, and lower prevalence of T2D and metabolic syndrome. Bromocriptine, a dopamine receptor agonist used to treat prolactinoma, is approved by Food and Drug Administration for treatment in type 2 diabetes mellitus since 2009. Prolactin lowering suppress insulin secretion and decrease insulin sensitivity, therefore dopamine receptor agonists which act at the pituitary to lower serum prolactin levels are expected to impair glucose tolerance. Making it more complicating, studies exploring the glucose-lowering mechanism of bromocriptine and cabergoline have resulted in contradictory results; while some demonstrated actions independently on prolactin status, others showed glucose lowering partly explained by prolactin level. Previous studies showed that a moderate increase in central intraventricular prolactin levels stimulates hypothalamic dopamine with a decreased serum prolactin level and improved glucose metabolism. Additionally, sharp wave-ripples from the hippocampus modulates peripheral glucose level within 10 minutes, providing evidence for a mechanistic link between hypothalamus and blood glucose control. Central insulin in the mesolimbic system have been shown to suppress dopamine levels thus comprising a feedback control loop. Central dopamine and prolactin levels plays a key role in the glucose homeostasis control, and their dysregulation could lead to the pathognomonic central insulin resistance depicted in the “ominous octet”. This review aims to provide an in-depth discussion on the glucose-lowering mechanism of dopamine receptor agonists and on the diverse prolactin and dopamine actions on metabolism targets. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10012161/ /pubmed/36993818 http://dx.doi.org/10.3389/fcdhc.2023.935872 Text en Copyright © 2023 Chien, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Clinical Diabetes and Healthcare
Chien, Hung-Yu
Chen, Su-Mei
Li, Wan-Chun
Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title_full Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title_fullStr Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title_full_unstemmed Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title_short Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
title_sort dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions
topic Clinical Diabetes and Healthcare
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012161/
https://www.ncbi.nlm.nih.gov/pubmed/36993818
http://dx.doi.org/10.3389/fcdhc.2023.935872
work_keys_str_mv AT chienhungyu dopaminereceptoragonistsmechanismofactionsonglucoseloweringandtheirconnectionswithprolactinactions
AT chensumei dopaminereceptoragonistsmechanismofactionsonglucoseloweringandtheirconnectionswithprolactinactions
AT liwanchun dopaminereceptoragonistsmechanismofactionsonglucoseloweringandtheirconnectionswithprolactinactions